Search Results
Your search for ,NOt matches 22378 pages
Showing 551 - 600Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma
Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precursor Asymptomatic Neoplasms by Group Effort Analysis–Smoldering Multiple Myeloma (PANGEA-SMM),...
AI Model for Predicting Oncotype DX 21-Gene Recurrence Score
As reported in The Lancet Oncology, Shamai et al have developed an artifical intelligence (AI) model based on digital histopathology slide images and clinical features to predict the Oncotype DX 21-gene recurrence score (RS) in patients with hormone receptor–positive, HER2-negative invasive breast...
AI As Collaborator in Cancer Research and in Clinical Care
Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identified patient datasets from participating cancer centers, while maintaining patient security,...
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New England Journal of Medicine, pioneering nephrologist and health economist William B. Schwartz, MD,...
Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk
The chances of breast cancer recurring remain low when patients are treated with radiotherapy that is tailored to their individual risk following chemotherapy and surgery. These are the findings of a 10-year Dutch study (RAPCHEM; BOOG 2010-03) presented at the 15th European Breast Cancer Conference ...
Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery
Women who are treated with mastectomy for breast cancer often choose to have breast reconstructive surgery using an implant. But hard, painful scar tissue can form around the implant, especially when women also receive radiotherapy as part of their treatment. Findings from the OPBC-09 PRExRT study, ...
Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma
In an interim analysis of a Chinese phase II/III trial (ZSAB) reported in The New England Journal of Medicine, Shi et al found that a neoadjuvant GOLP regimen (gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor [toripalimab]) improved event-free survival vs no neoadjuvant treatment in...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
In Celebration of a Decades-Long Journey of Discovery and Innovation
On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds the titles of Director of Dana-Farber/Harvard Cancer Center, the Richard and Susan Smith Professor of ...
POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings
POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monoclonal plasma cell dyscrasia, and skin changes. Clinical manifestations are thought to result from...
How AI Is Already Having a Significant Impact on Cancer Care
Three education sessions presented during the 2025 ASCO Annual Meeting showcased how artificial intelligence (AI) is quickly transforming cancer care from clinical trial planning and ambient scribes transcribing physician-patient conversations to therapeutic decision-making. The meeting also...
A Decade of Research Leads to New Guidance on Using Colony-Stimulating Factors in Anticancer Treatment
ASCO has published an updated guideline describing the latest evidence on using hematopoietic colony-stimulating factor (CSF) to support anticancer treatment, namely chemotherapy and stem cell transplantation.1 “We wanted to update these guidelines both to include the newer evidence as well as...
New First-Line Targeted Therapy Recommendations Among Updated ASCO Guidance on Gastroesophageal Cancer Management
ASCO has released a guideline update addressing advances in the use of immunotherapy and targeted therapy for the treatment of advanced gastroesophageal cancer.1 The guideline, last updated in 2023 to include first-line therapy recommendations for patients with biomarkers such as PD-L1 and HER2,...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New U.S. Dietary Guidelines, Survey Finds
Public awareness of the link between drinking alcohol and elevated cancer risk remains unchanged since February 2025, with over half of Americans saying that regularly consuming alcohol increases your chances of later developing cancer, according to a new survey by the Annenberg Public Policy...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer
Biomarker discovery in colorectal cancer has traditionally focused on identifying molecular alterations with broad prognostic or predictive utility. However, evidence is increasingly suggesting that biomarkers do not have universal prognostic or predictive value across patient sets but instead...
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers have found a combination of the tyrosine kinase inhibitor tucatinib and the monoclonal antibody trastuzumab, plus the chemotherapy capecitabine, may improve symptoms and extend survival in some...
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
On March 20, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical Hodgkin lymphoma. The FDA also granted traditional...
Melanoma-Specific Survival With Sentinel Lymph Node Biopsy
In a systematic review and meta-analysis reported in The Lancet Oncology, Varey et al found that patients undergoing sentinel node biopsy (SLNB) for melanoma had reduced risk of melanoma-specific mortality and disease recurrence vs those who did not undergo SLNB. Study Details The analysis included ...
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response...
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges. This annual survey on...
Study Finds No Overall Increase in Cancer Risk After Medically Assisted Reproduction
Overall cancer incidence is similar between women who have used medically assisted reproduction and the general population, but certain cancers may occur at slightly higher rates, according to an Australian population–based cohort study published in JAMA Network Open by Vajdic et al. The...
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with...
SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy
As the incidence of cancer among reproductive-age people continues to increase in the United States—with approximately one out of every 1,000 pregnancies complicated by cancer—the Society for Maternal-Fetal Medicine (SMFM) has issued its first evidence-based clinical guidance for diagnosing and...
Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
A new analysis suggests that prostate cancer screening may compare favorably with screening for breast cancer in terms of identifying significant cancers, reducing mortality, and avoiding unnecessary harms, according to findings presented at the 2026 Annual Congress of the European Association of...
Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria
One in 10 patients who present to the emergency department with visible hematuria may die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study, presented at the European Association of Urology Congress (EAU26) in London, found that a scan administered within 48...
Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer
The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients with locally advanced/metastatic urothelial carcinoma. The results from the randomized phase III...
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal Cancers Symposium. Of 41 evaluable patients treated with single-agent...
PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%
A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biopsy, according to first results from the phase III PRIMARY2 trial presented at the 2026 Annual...
Addition of Tislelizumab to Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer
As reported in JAMA Oncology by Yang et al, the 3-year follow-up of the predominantly Chinese phase III RATIONALE-309 trial showed a maintained progression-free survival benefit with the addition of first-line tislelizumab to chemotherapy in patients with recurrent or metastatic nasopharyngeal...
Forgotten Lessons From South Africa
On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New...
Women More Likely to Survive Cancer—But Suffer More Severe Side Effects
Women are more likely to survive cancer than men, but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study. Published by Chhetri et al in the Journal of the National Cancer Institute, the research identified consistent differences...
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
In a Chinese phase III trial (CAMPASS) reported in The Lancet Oncology, Zhong et al found that the PD-L1 inhibitor benmelstobart plus the tyrosine kinase inhibitor anlotinib significantly improved progression-free survival vs placebo plus pembrolizumab in the first-line treatment of PD-L1–positive...
Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia
New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that the method provided reliable and robust analytical performance with high sensitivity and specificity in detecting genetic alterations. In nearly 20% of cases,...
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
Recurrence-free survival was similar between adjuvant therapy with the PD-1 inhibitor pembrolizumab and placebo in patients with hepatocellular carcinoma who achieved a complete radiologic response after surgical resection or local ablation, based on the phase III KEYNOTE-937 trial.1 Presented at...
Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence
Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrence following a nephrectomy. Now, results from the phase III LITESPARK-022 study investigating the...
BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma
In a Chinese phase II study (CAREMM-001) reported in the Journal of Clinical Oncology, Yan et al found that B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was highly active in patients with newly diagnosed multiple myeloma who were ineligible for or did not proceed...
Disease Stage at Breast Cancer Diagnosis Impacted by Region, Race, and Insurance
Significant differences were found in advanced-stage diagnoses of breast cancer in rural populations according to geographic location in the United States, which were further influenced by demographic factors of race and insurance status, according to findings from an analysis of the National...
Can Viral Respiratory Infections Increase Lung Cancer Risk?
Severe COVID-19 and influenza infections may prime the lungs for cancer and can accelerate the disease’s development—but vaccination heads off those harmful effects, according to new research published by Qian et al in Cell. University of Virginia (UVA) School of Medicine researcher Jie Sun, PhD,...
Early Study Evaluates Two-Vaccine Strategy in T-Cell Lymphoma
T-cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can’t easily distinguish cancerous T cells from healthy ones. Now, scientists at The Wistar Institute have designed a two-vaccine approach that not only...
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
A structured exercise program in patients with cancer receiving chemotherapy led to a reduction in self-reported cognitive impairment vs those receiving chemotherapy who were not on an exercise plan, according to findings from a nationwide, randomized phase III trial published in JNCCN—Journal of...
Risk of Breast Cancer After Ovarian Cancer in Women With BRCA1/2 Variants
In a study reported in the Journal of Clinical Oncology, investigators from the Hereditary Breast Cancer Clinical Study Group found that women with ovarian cancer with pathogenic/likely pathogenic BRCA1/2 variants had low risk for subsequent breast cancer. Study Details The study involved an...
Metastatic Uveal Melanoma: Nivolumab/Ipilimumab Plus Percutaneous Hepatic Perfusion
In a Dutch single-center phase II trial (CHOPIN) reported in The Lancet Oncology, van den Hoek et al found that the addition of nivolumab and ipilimumab to percutaneous hepatic perfusion improved progression-free survival in patients with metastatic uveal melanoma. Study Details Seventy-six...
AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden
Integration of artificial intelligence (AI) into screening workflows increased the detection of breast cancer by 10.4% in the United Kingdom, according to the results of the GEMINI study published in Nature Cancer. Additionally, use of AI in different workflows led to reductions in workload by up...
Prostate Cancer: Low Testosterone Levels May Be Associated With Increased Risk of Progression During Surveillance
A new study has found that patients with prostate cancer and low testosterone levels may have a higher risk of their cancer progressing to a more aggressive form while under active surveillance. The findings, published by Lawen et al in the The Journal of Urology, suggest that baseline testosterone ...
FDA Releases Updated Guidance on Biosimilar Development
The U.S. Food and Drug Administration (FDA) has released a new draft guidance to streamline the development of biosimilars. This, and prior versions of the draft guidance for industry, reflect actions being taken by the agency to lower the cost of drugs. “Streamlining biosimilar development...
Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer
In an Italian single-center phase II trial (SURE-02) reported in The Lancet Oncology, Necchi et al found that neoadjuvant sacituzumab govitecan-hziy plus perioperative pembrolizumab produced a “promising” clinical complete response rate in patients with muscle-invasive bladder cancer who were...
SABCS 2025: High-Level Review of Select Data
The 2025 San Antonio Breast Cancer Symposium (SABCS 2025) featured some exciting presentations. The early breast cancer highlights at SABCS 2025 included the landmark lidERA trial, which explored the efficacy of the oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant...
Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors
In a European phase II/III trial (AXINET) reported in the Journal of Clinical Oncology, Garcia-Carbonero et al found that the addition of axitinib to long-acting octreotide appeared to show activity in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). Study Details The...
